| Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma. | Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma.
Zhan S, Qiu M, Wei X, Wei J, Qin L, Jiang B, Wen Q, Chen P, Lin Q, Wei X, Zhou Z, Jiang Y, Liang X, Li R, Liu Y, Yu H., Free PMC Article | 09/12/2024 |
| GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells. | GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells.
Chu YD, Fan TC, Lai MW, Yeh CT., Free PMC Article | 11/19/2022 |
| GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway. | GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway.
Li HW, Liu MB, Jiang X, Song T, Feng SX, Wu JY, Deng PF, Wang XY. | 03/5/2022 |
| GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma. | GALNT2/14 overexpression correlate with prognosis and methylation: potential therapeutic targets for lung adenocarcinoma.
Yu Y, Wang Z, Zheng Q, Li J. | 06/12/2021 |
| A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. | A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. | 01/9/2021 |
| GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers. | GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers.
Lin WR, Yeh CT., Free PMC Article | 11/21/2020 |
| Effects of IGFBP-3 and GalNAc-T14 on proliferation and cell cycle of glioblastoma cells and its mechanism. | Effects of IGFBP-3 and GalNAc-T14 on proliferation and cell cycle of glioblastoma cells and its mechanism.
Yang J, Hu Y, Wu J, Kong S. | 11/21/2020 |
| Data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14. Studies provide evidence that aberrant expression of BORIS may play a role in the progression to HGSC by enhancing the migratory and invasive properties of FTSEC. | BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
Hillman JC, Pugacheva EM, Barger CJ, Sribenja S, Rosario S, Albahrani M, Truskinovsky AM, Stablewski A, Liu S, Loukinov DI, Zentner GE, Lobanenkov VV, Karpf AR, Higgins MJ., Free PMC Article | 07/18/2020 |
| Silencing of GALNT14 in osterix-overexpressed cells restored the decreased chemosensitivity. Conversely, overexpression of GALNT14 in osterix-knockdown cells abrogated the increased chemosensitivity in breast cancer cells. | Osterix Decreases the Chemosensitivity of Breast Cancer Cells by Upregulating GALNT14.
Wu J, Chen X, Bao Q, Duan R, Jin Y, Shui Y, Yao B, Lu X, Wang Y, Cui H, Li L, Yuan H, Ma C. | 01/20/2018 |
| The analysis showed that the "TT" genotype was associated with unfavorable overall survival (OS, P = 0.009). | GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK, Yeh CT., Free PMC Article | 02/4/2017 |
| miR-125a functions as tumor suppressor in ovarian cancer by targeting GALNT14. | MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.
Yang J, Li G, Zhang K. | 02/4/2017 |
| GALNT14 genotypes were significantly associated with clinical outcomes of transcatheter arterial chemoembolization. | GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. | 10/1/2016 |
| Expression of GalNAc-T14 or HOXB9 was strongly correlated with reduced recurrence-free survival in lung adenocarcinomas. | GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.
Kwon OS, Oh E, Park JR, Lee JS, Bae GY, Koo JH, Kim H, Choi YL, Choi YS, Kim J, Cha HJ., Free PMC Article | 10/1/2016 |
| Recurrence of mutation suggests GALNT14 as a novel gene potentially involved in neuroblastoma predisposition. | Identification of GALNT14 as a novel neuroblastoma predisposition gene.
De Mariano M, Gallesio R, Chierici M, Furlanello C, Conte M, Garaventa A, Croce M, Ferrini S, Tonini GP, Longo L., Free PMC Article | 07/30/2016 |
| GALNT14 stimulates MMP-2 expression. | GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7.
Huanna T, Tao Z, Xiangfei W, Longfei A, Yuanyuan X, Jianhua W, Cuifang Z, Manjing J, Wenjing C, Shaochuan Q, Feifei X, Naikang L, Jinchao Z, Chen W. | 12/12/2015 |
| GALN14 genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced hepatocellular carcinoma (HCC) patients treated by FMP chemotherapy. | A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Yeh CT, Liang KH, Lin CC, Chang ML, Hsu CL, Hung CF. | 02/15/2014 |
| Studies demonstrate that IGFBP-3 and GalNAc-T14 are colocalized in MCF-7 cells, and confirmed the interaction between IGFBP-3 and GalNAc-T14; these results reveal a minimal region of GalNAc-T14 that was sufficiently bound to the full-length IGFBP-3. | Colocalization and identification of interaction sites between IGFBP-3 and GalNAc-T14.
Wu C, Ma SS, Ge JF, Wang YY, Tian HN, Liu XB, Zhang B, Liu FM, Zhang XK, Li QJ. | 07/14/2012 |
| Observational study of gene-disease association. (HuGE Navigator) | Investigation of genetic susceptibility factors for human longevity - a targeted nonsynonymous SNP study.
Flachsbart F, Franke A, Kleindorp R, Caliebe A, Blanché H, Schreiber S, Nebel A. | 12/5/2010 |
| Results provide evidence that GalNAc-T14 may be a potential biomarker for breast cancer by immunohistochemistry. | N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H, Zhu M., Free PMC Article | 08/23/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| GALNT14 and FUT3/6 H-scores were significantly higher in non-small cell lung cancer cell lines sensitive to dulanermin and drozitumab versus resistant cell lines | Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.
Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. | 05/31/2010 |
| GALNT14 may be involved in regulating the apoptotic action of IGFBP-3. | GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3.
Wu C, Shan Y, Liu X, Song W, Wang J, Zou M, Wang M, Xu D. | 01/21/2010 |
| The role of GalNAc-T14 as an intracellular mediator of the effects of IGFBP-3 need to be verified in future studies. | N-Acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner.
Wu C, Yao G, Zou M, Chen G, Wang M, Liu J, Wang J, Xu D. | 01/21/2010 |
| cloning and characterization; results provide evidence that pp-GalNAc-T14 is a new member of the pp-GalNAc-T family and suggest that it may be involved in the O-glycosylation in kidney | Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14.
Wang H, Tachibana K, Zhang Y, Iwasaki H, Kameyama A, Cheng L, Guo Jm, Hiruma T, Togayachi A, Kudo T, Kikuchi N, Narimatsu H. | 01/21/2010 |